

Global Organ Transplant Immunosuppressant Drugs Market Report 2024: Trends, Strategies, And Opportunities

The Business Research Company's Organ Transplant Immunosuppressant Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK,
August 12, 2024 /EINPresswire.com/ --

The global [organ transplant immunosuppressant drugs market](#) is projected to grow from \$5.24 billion in 2023 to \$5.42 billion in 2024, at a CAGR

of 3.4%. This steady growth can be attributed to the rising number of transplant procedures, advancements in healthcare infrastructure, and increasing awareness. The market is expected to reach \$6.29 billion by 2028 at a CAGR of 3.8%, with a slightly accelerated CAGR of 3.8%, driven by emerging therapies, a rise in organ failure cases, and the expansion of personalized medicine.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs”

*The Business Research
Company*

Increasing Demand for Organ Transplantation Boosts
Market Growth

The growing demand for organ transplantation is a key driver for the organ transplant immunosuppressant drugs market. Organ transplantation involves replacing a damaged or diseased organ with a healthy one from a donor, and immunosuppressant drugs are critical to

preventing organ rejection. The success of these surgeries heavily relies on the availability and efficacy of immunosuppressant drugs. In 2021, the Global Observatory on Donation and Transplantation (GODT) reported a 144,302 annual organ transplant count, marking an 11.3% increase from the previous year. This trend is expected to continue, driving further growth in the market.

Explore comprehensive insights into the global organ transplant immunosuppressant drugs market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=10143&type=smp



The Business
Research Company

Organ Transplant Immunosuppressant Drugs Global
Market Report 2024 – Market Size, Trends, And Global
Forecast 2024-2033

Key Players and Market Trends

Major companies in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, and Pfizer Inc. These companies are focusing on product innovation to strengthen their market positions. For example, combination therapies, which involve using two or more immunosuppressant drugs, are becoming more popular due to their ability to enhance immunosuppression while minimizing side effects. In July 2021, the U.S. FDA approved Prograf, an immunosuppressant drug, for use in combination with other drugs to prevent organ rejection in patients receiving kidney, liver, or heart transplants.

Segments:

- Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Others
- Drug Classes
- Transplant Type: Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Geographical Insights: North America Leading the Market

North America led the organ transplant immunosuppressant drugs market in 2023, largely due to advanced healthcare systems and a high number of transplant procedures. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by increasing healthcare investments and rising awareness of organ transplantation.

Explore the report store to make a direct purchase of the report

<https://www.thebusinessresearchcompany.com/report/organ-transplant-immunosuppressant-drugs-global-market-report>

Organ Transplant Immunosuppressant Drugs Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Organ Transplant Immunosuppressant Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on [organ transplant immunosuppressant drugs market size](#), organ transplant immunosuppressant drugs market drivers and trends, organ transplant immunosuppressant drugs market major players, competitors' revenues, market positioning, and market growth across geographies. The organ transplant immunosuppressant drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into

segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Organic Pharmaceutical Excipients Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/organic-pharmaceutical-excipients-global-market-report>

Anticoccidial Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/anticoccidial-drugs-global-market-report>

Immunosuppressants Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/734260195>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.